JAN 03, 2017 8:30 PM PST

Dendritic Cell Vaccines Promising For Breast Cancer

WRITTEN BY: Kara Marker

A vaccine for cancer is on the horizon, although it works in a way different to what most people might consider a conventional vaccine. Using a personalized approach, scientists from the Moffitt Cancer Center are on the brink of a new treatment option for breast cancer patients.

Researchers tested the safety and efficacy of the new vaccine technology in a clinical trial with 54 women all diagnosed with early-stage breast cancer. The other quality these women shared was that their breast cancer cells expressed HER2, a protein that is overexpressed in nearly a quarter of all breast cancers and which is unfortunately linked to cases of a particularly aggressive cancer and a poor prognosis.

Expressing HER2 works for cancer cells because immune cells that are designed to fight tumors cannot recognize and target cancer cells as well when they display this protein on their cell surface, as if the immune system didn’t already have enough on its plate in a case of cancer.

This is where the idea came to create a vaccine of sorts, designed for dendritic cells. The vaccine helps the immune system relearn to recognize HER2, and researchers could extract dendritic cells from each breast cancer patient to cater a dendritic cell vaccine specifically to each person.

Vaccines in the clinical trial were reinjected into a lymph node, breast tumor, or both once a week for six weeks. Results showed that the treatment was well received and women experienced only low-grade toxicity, if any. Not many cancer treatments can say the same. Very few side effects occurred, with the most common being fatigue, injection site reactions, and chills.

Remarkably, researchers saw a clear immune response to the vaccine in 80 percent of evaluable patients, and all of the responses were similar despite variation of vaccine administration location.

"These results suggest that vaccines are more effective in [ductal carcinoma in situ (DCIS, an early non-invasive disease)], thereby warranting further evaluation in DCIS or other minimal disease settings, and the local regional sentinel lymph node may serve as a more meaningful immunologic endpoint," explained Brian J. Czerniecki, MD, PhD

The present study was published in the journal Clinical Cancer Research.

Source: Moffitt Cancer Center

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAR 23, 2020
Drug Discovery & Development
MAR 23, 2020
Top 5 Candidates for Coronavirus Vaccine Around the World
It’s easy to complain about the role of big pharma in medicine-making and the hassle of dealing with protective pa ...
MAR 29, 2020
Cell & Molecular Biology
MAR 29, 2020
Learning More About Boosting Immunity in Older Adults
Older adults are more susceptible to infections and don't generate a robust immune response after a vaccination.
APR 08, 2020
Immunology
APR 08, 2020
How the Skin Shields Against Zika Infection
Aedes mosquitoes are native of Africa but are commonly found in regions of the Americas, Asia, and the Pacific. These da ...
APR 16, 2020
Health & Medicine
APR 16, 2020
Structural Basis of Receptor Recognition by SARS-CoV-2
As mortality and infection rates rise globally, it appears that SARS-CoV-2, the virus responsible for the COVID-19 pande ...
APR 23, 2020
Immunology
APR 23, 2020
COVID "Immunity Passports" Are a No-Go
  Authorities are caught between dealing with the competing urgencies of abating the COVID-19 health crisis and the ...
MAY 18, 2020
Microbiology
MAY 18, 2020
An Antibody Against SARS May Neutralize SARS-CoV-2
SARS-CoV caused an outbreak of SARS in 2003. Samples collected from those patients back then may help us against SARS-Co ...
Loading Comments...